Inogen reports preliminary Q4 revenue $82M, consensus $88.6M

Reports preliminary FY25 revenue $349M, consensus $355.5M. “While fourth quarter results continued to reflect strong performance in our business-to-business channels, we experienced a shift in the timing of a few large customer orders into the first half of 2026. Although this delay relative to expectations is disappointing, our full year results continued to make meaningful progress in executing our business turnaround,” said Kevin Smith, president and CEO. “Highlights for the full year include positive revenue growth, advancing toward profitability, and expanding the innovation pipeline with launches of the Voxi 5 stationary oxygen concentrator and Aurora Masks for Obstructive Sleep Apnea patients in the U.S. The Inogen (INGN) team remains confident in our ability to drive growth acceleration and profitability into 2026, and we look forward to sharing additional details and 2026 financial guidance during our February earnings call.”